{"entity":{"id":"nct05727904","kind":"trial","name":"Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.","aka":[],"tldr":"A phase 3 trial of Pembrolizumab in melanoma, run by Iovance Biotherapeutics, Inc., now recruiting.","summary":"Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma. is a phase 3 interventional study registered as NCT05727904 by Iovance Biotherapeutics, Inc., with 670 participants planned, started 2023-03-30 and due to reach its primary completion in 2028-03-01. Interventions recorded: Lifileucel plus Pembrolizumab, Pembrolizumab with Optional Crossover Period. Conditions listed: Metastatic Melanoma, Unresectable Melanoma, Melanoma. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05727904","url":"https://clinicaltrials.gov/study/NCT05727904"}],"tags":["ctgov-ingest"],"related":[],"cancers":["melanoma","advanced-melanoma"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["pembrolizumab"],"companies":["iovance"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05727904","phase":"3","setting":"A Phase 3, Multicenter, Randomized, Open-label, Parallel Group, Treatment Study to Assess the Efficacy and Safety of the Lifileucel (LN-144, Autologous Tumor Infiltrating Lymphocytes [TIL]) Regimen in Combination With Pembrolizumab Compared With Pembrolizumab Monotherapy in Participants With Untreated, Unresectable or Metastatic Melanoma","sponsor":"Iovance Biotherapeutics, Inc.","participation":[{"nct":"NCT05727904","source":"https://clinicaltrials.gov/study/NCT05727904","fetchedAt":"2026-10-07T16:53:52.193Z","studySha256":"2fa490214a8d2f7ca45638c598e496ad320972fb73fc517bd18a673070517ca9","overallStatus":"RECRUITING","lastUpdatePosted":"2026-09-24","leadSponsor":"Iovance Biotherapeutics, Inc.","collaboratorCount":0,"minimumAge":"18 Years","maximumAge":"70 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":670,"enrolmentType":"ESTIMATED","siteCount":82,"recruitingSiteCount":71,"countries":["Australia","Belgium","Canada","Finland","France","Germany","Israel","Italy","Netherlands","Singapore","South Korea","Spain","Sweden","Switzerland","United Kingdom","United States"]}],"started":"2023-03-30","startedType":"actual","enrolled":670,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05727904/","neighbours":{"cancer":[{"id":"advanced-melanoma","kind":"cancer","name":"Advanced melanoma (unresectable stage III and stage IV)","route":"/cancers/advanced-melanoma/"},{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"company":[{"id":"iovance","kind":"company","name":"Iovance Biotherapeutics","route":"/companies/iovance/"}]}}